Alta Sciences
JUNE 6, 2025
About the Author Martin Rougée joined Altasciences in early 2024 as an Optimization Scientist. After completing his doctorate, he moved into the industry by joining a startup that specialized in enzymatic DNA synthesis, where he enhanced their processes and reagents using automated liquid handling technology.
Broad Institute
APRIL 5, 2025
During his doctoral research at University of California Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He is the 2022 King Faisal Prize Laureate in Medicine, and the recipient of the 2024 Gabbay Award in Biotechnology and Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 11, 2024
2024: 25(7):853-864. 2024: 84(6). He holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. The Lancet Oncology. Available from: [link] 2 Ellmark P, Deronic A, Hagerbrand K, et al. Available from: [link] 3 Andersson H, Celander M, Ellmark P, et al.
Alta Sciences
MARCH 4, 2025
She earned a doctorate in Pharmacology and the Collaborative Program in Neuroscience from the University of Torontowhere she currently holds an appointment as an Adjunct Professor. In 2024, she was recognized as a PharmaVoice 100 honoree , and named one of the 30 Most Influential People in the Pharma Industry by The Medicine Maker.
Drug Target Review
JUNE 5, 2025
Studies presented at the American Society of Hematology 2024 Annual Meeting have predicted that patients receiving regular aRBCX would save up to $100,000 per patient lifetime to the healthcare system compared to other transfusion modalities, while increasing quality of life. 2024 Sep 10;2:101875. Blood Adv (2024) 8 (4): 10181029.
Codon
NOVEMBER 3, 2024
Based on early successes in animal experiments, doctors tested the vaccine on an infant whose mother had died of TB shortly after giving birth. ” Asimov Press (2024). The infant experienced no adverse effects, thereby suggesting the vaccine was safe. Cite: Nahas, Kamal. “The Long Road to End Tuberculosis.”
BioPharma Drive: Drug Pricing
JUNE 11, 2025
And though Roche and Bristol Myers acquired both their medicines in high-priced acquisitions, they haven’t yielded significant sales: Rozlytrek generated about 134 million Swiss francs in 2024 , while Augtyro pulled in just $38 million.
Expert insights. Personalized for you.
Let's personalize your content